Abstract 2306: BLU-222, an investigational, potent, and selective CDK2 inhibitor, demonstrated robust antitumor activity in <i>CCNE1</i>-amplified ovarian cancer models
Victoria E. Brown(Tufts University), Yoon Jong Choi(Blueprint Medicines (United States)), Michelle Maynard(Froedtert Hospital), Maxine Chen(Blueprint Medicines (United States)), Phil Ramsden(Blueprint Medicines (United States)), Jian Guo(Yangzhou University), Nealia C. House(Blueprint Medicines (United States)), Richard Vargas(Blueprint Medicines (United States)), Emanuele Perola(Blueprint Medicines (United States)), Ruduan Wang(Blueprint Medicines (United States)), Steve Wenglowsky(Blueprint Medicines (United States)), Neil Bifulco(Blueprint Medicines (United States)), Joseph Kim(Beth Israel Deaconess Medical Center), Douglas Wilson(Blueprint Medicines (United States)), Dean Zhang(Blueprint Medicines (United States)), Riadh Lobbardi(Massachusetts General Hospital)
Cited by 13
Related Papers
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
|Cancer Discovery|2018|397
Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2
|American Journal of Physiology-Heart and Circulatory Physiology|2005|199
Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment
|Gastrointestinal Endoscopy|2018|158
Aging Mouse Hearts Are Refractory to Infarct Size Reduction With Post-Conditioning
|Journal of the American College of Cardiology|2008|126
Cardioprotection with Postconditioning: Loss of Efficacy in Murine Models of Type-2 and Type-1 Diabetes
|Antioxidants and Redox Signaling|2010|123